EC Number   |
Disease |
PubMed ID |
Title of Publication  |
Category |
Confidence Level |
|---|
   1.1.1.43 | Neoplasms |
33817181 |
1-Hydroxy-8-methoxy-anthraquinon Reverses Cisplatin Resistance by Inhibiting 6PGD in Cancer Cells. |
therapeutic application
unassigned |
1
0 |
| 1.1.1.43 | Down Syndrome |
4260604 |
6-phosphogluconate dehydrogenase (6-P-GD) in Down's syndrome. |
unassigned |
0 |
| 1.1.1.43 | Neoplasms |
14288104 |
6-PHOSPHOGLUCONATE DEHYDROGENASE ACTIVITY IN VAGINAL FLUID: LIMITATIONS AS A SCREENING TEST FOR GENITAL CANCER. |
diagnostic usage
therapeutic application
unassigned |
4
1
0 |
| 1.1.1.43 | phosphogluconate 2-dehydrogenase deficiency |
11233775 |
6-Phosphogluconate dehydrogenase deficiency in an Italian family. |
causal interaction
diagnostic usage
unassigned |
4
2
0 |
| 1.1.1.43 | Uterine Cervical Neoplasms |
14341115 |
6-PHOSPHOGLUCONATE DEHYDROGENASE ESTIMATION IN VAGINAL FLUID IN THE DIAGNOSIS OF CERVICAL CANCER. |
diagnostic usage
unassigned |
4
0 |
| 1.1.1.43 | Carcinogenesis |
32039535 |
6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
3
1 |
| 1.1.1.43 | Neoplasm Metastasis |
32039535 |
6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
3
1 |
| 1.1.1.43 | Neoplasms |
32039535 |
6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
3
1 |
| 1.1.1.43 | Uterine Neoplasms |
14308735 |
6-PHOSPHOGLUCONATE DEHYDROGENASE IN UTERINE CANCER DETECTION. |
diagnostic usage
unassigned |
1
0 |
| 1.1.1.43 | Carcinogenesis |
26479318 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
1
2
4 |
